文献速递产科母胎医学

疑似或确诊子痫前期孕妇妊娠期间及产后可溶性fms样酪氨酸激酶-1与胎盘生长因子的动力学变化

Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-05-06

本研究为探索性研究,对前瞻性队列研究进行二次分析,纳入2013年12月至2016年4月于鹿特丹Erasmus医学中心产科招募的单胎妊娠、疑似或确诊子痫前期的孕妇。第一组46例孕期至少两次检测sFlt-1/PlGF比值,基线比值≤38的30例中27例比值稳定长达100天,其余3例及基线比值>38的16例中多数比值进一步升高。第二组26例子痫前期或HELLP综合征患者产后sFlt-1降至产前值的<1%,半衰期1.4±0.3天,PlGF降至约30%,半衰期3.7±4.3天。

要点

  • 基线sFlt-1/PlGF比值≤38的30例中27例比值稳定长达100天,其余3例比值升高。
  • 基线sFlt-1/PlGF比值>38的16例中多数比值进一步升高。
  • 产后sFlt-1降至产前值的<1%,半衰期1.4±0.3天;PlGF降至约30%,半衰期3.7±4.3天。

核心结论

  • 基于此小样本队列,因疑似或确诊子痫前期入院且sFlt-1/PlGF比值≤38的孕妇中,高达10%在随后数周出现比值升高,提示需重复测定sFlt-1/PlGF比值以最终排除子痫前期诊断。
  • 子痫前期/HELLP综合征患者产后sFlt-1水平快速且显著下降,提示sFlt-1与PlGF不同,几乎完全来源于胎盘。

研究设计与样本

  • 探索性研究,对一项前瞻性队列研究进行二次分析。
  • 2013年12月至2016年4月在鹿特丹Erasmus医学中心产科招募单胎妊娠、疑似或确诊子痫前期的孕妇,孕周从18周起。
  • 采用Roche Diagnostics Elecsys检测sFlt-1和PlGF。
  • 第一组:疑似或确诊子痫前期孕妇,孕期至少两次检测sFlt-1和PlGF(n=46),纳入时中位孕周26周(范围18-40周)。
  • 第二组:子痫前期或HELLP综合征孕妇,产前和产后检测sFlt-1和PlGF(n=26),纳入时中位孕周29周(范围16-37周),产前检测至分娩的中位时间2天(范围1-17天)。

主要发现

  • 第一组基线sFlt-1/PlGF比值≤38的30例中,27例比值稳定长达100天,其余3例比值升高。
  • 第一组基线sFlt-1/PlGF比值>38的16例中,多数比值进一步升高。
  • 第二组产后sFlt-1降至产前值的<1%,半衰期1.4±0.3天。
  • 第二组产后PlGF降至产前值的约30%,半衰期3.7±4.3天。

局限性

  • 基于此小样本队列。
  • 高达10%的孕妇在随后数周出现sFlt-1/PlGF比值升高,提示需重复测定以最终排除子痫前期诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the evolution of the soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) ratio in women with suspected or confirmed pre-eclampsia (PE), and to investigate the changes in sFlt-1 and PlGF levels in pre-eclamptic women after delivery. METHODS: This was an exploratory study in which secondary analysis was performed on a prospective cohort study that enrolled women with a singleton pregnancy and suspected or confirmed PE from 18 weeks' gestation, carried out between December 2013 and April 2016 at the Department of Obstetrics of the Erasmus Medical Center in Rotterdam. sFlt-1 and PlGF were determined using Roche Diagnostics Elecsys assays in two groups of patients. In the first group, patients with suspected or confirmed PE had sFlt-1 and PlGF levels measured at least twice during their pregnancy. Changes in these biomarkers over the course of pregnancy were compared for patients in this group with a baseline sFlt-1/PlGF ratio of ≤ 38 and for those with a ratio > 38. In the second group, sFlt-1 and PlGF levels of women with PE or HELLP syndrome were measured before and after delivery. For this group, pre- and postpartum sFlt-1 and PlGF levels were compared and half-lives were calculated. RESULTS: Women with suspected or confirmed PE for whom sFlt-1 and PlGF levels were measured at least twice during pregnancy (n = 46) had a median gestational age at inclusion of 26 weeks (range, 18-40 weeks). In 27 of the 30 patients with sFlt-1/PlGF ratio ≤ 38 at baseline, thereby ruling out PE, the sFlt-1/PlGF ratio remained stable for up to 100 days. In the remaining three patients with a ratio ≤ 38 and in most of the 16 patients with a ratio > 38, the ratio increased further. For women diagnosed with PE or HELLP syndrome for whom sFlt-1 and PlGF levels were measured before and after delivery (n = 26), median gestational age at inclusion was 29 weeks (range, 16-37 weeks) and median time between antepartum measurement and delivery was 2 days (range, 1-17 days). In this group, after delivery, sFlt-1 dropped to < 1% of its pre-delivery value, with a half-life of 1.4 ± 0.3 days, while PlGF dropped to ∼30% of its pre-delivery value, with a half-life of 3.7 ± 4.3 days. CONCLUSIONS: Based on this small cohort, up to 10% of pregnant women admitted with suspected or confirmed PE presenting with a sFlt-1/PlGF ratio of ≤ 38 display a rise in sFlt-1/PlGF ratio in subsequent weeks, implying that repeat determination of the sFlt-1/PlGF ratio is required to exclude definitively a diagnosis of PE. Furthermore, the rapid and pronounced decline in sFlt-1 levels after delivery in patients with PE/HELLP syndrome suggests that sFlt-1, in contrast to PlGF, is almost entirely derived from the placenta. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Saleh L, van den Meiracker AH, Geensen R, et al. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2018. PMID: 28600845. doi:10.1002/uog.17547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。